^
    Back
    Association details:
    Biomarker:BRAF V600_K601delinsE
    Cancer:Non Small Cell Lung Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    1968p - The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

    Published date:
    09/14/2020
    Excerpt:
    ...advanced NSCLC patients before dabrafenib and trametinib treatment were included...A BRAF p.(V600E) was identified in 35 patients and a p.(V600_K601delinsE) was observed in one patient.Patients with and without concurrent mutations had a PFS of 20.3 and 10.2 months...The patient with a BRAF p.(V600_K601delinsE) responded to the treatment and had a PFS of 5 months.